SCHEMBL2180207

SCHEMBL2180207

O=[N+]([O-])c1ccc(S(=O)(=O)Nc2ccncn2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.53
CA12 O43570 2/20 0.53
CA9 Q16790 2/20 0.53
NFKBIA P25963 1/20 0.51
RELA Q04206 1/20 0.51
KMT2A Q03164 4/20 0.50
CA1 P00915 3/20 0.50
MEN1 O00255 3/20 0.50
MMP1 P03956 1/20 0.50
MMP2 P08253 1/20 0.50
MMP9 P14780 1/20 0.50
MMP8 P22894 1/20 0.50
MMP13 P45452 1/20 0.50
GAA P10253 1/20 0.50
CA3 P07451 1/20 0.50
CA4 P22748 1/20 0.50
CA6 P23280 1/20 0.50
CA5A P35218 1/20 0.50
CA7 P43166 1/20 0.50
CA13 Q8N1Q1 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2407197 0.82 L3MBTL1 (0.66) CA2CA12CA9NFKBIARELA
SCHEMBL18843940 0.81 SCN9A (0.54) ALDH1A1KDM4E
SCHEMBL2179037 0.81 SMN1; SMN2 (0.65) KMT2AMEN1ALDH1A1EDNRATDP1
SCHEMBL1576354 0.81 ALDH1A1 (0.57) KMT2AMEN1GAAALDH1A1TDP1
SCHEMBL1094173 0.81 POLB (0.55) GAAALDH1A1KDM4E
SCHEMBL2180044 0.78 KMT2A (0.55) CA2CA12CA9KMT2ACA1
SCHEMBL30913863 0.78 KMT2A (0.52) CA2CA12CA9NFKBIARELA
SCHEMBL29225745 0.78 KMT2A (0.52) CA2CA12CA9NFKBIARELA
SCHEMBL28319395 0.78 SLC22A12 (0.45) KDM4E
SCHEMBL29440555 0.76 AURKA (0.63) CA2CA12CA9NFKBIARELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2013-01-24 US disclosed
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2013-01-24 US disclosed
WO-2011082400-A2 MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-07-07 WO disclosed
WO-2011082400-A2 MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof CD274, PDCD1LG2, PDCD1 CA2 4844/4885CA12 4713/4885CA9 4403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.